TrialCancer immunology, immunotherapy : CII2021

CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease.

Wenyi Lu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.